Skip to main navigation Skip to search Skip to main content

Cosyntropin testing does not predict response to glucocorticoids in community-acquired pneumonia in a randomized controlled trial

  • Claudine A. Blum*
  • , Philipp Schuetz
  • , Nicole Nigro
  • , Bettina Winzeler
  • , Birsen Arici
  • , Julie Refardt
  • , Sandrine A. Urwyler
  • , Nicolas Rodondi
  • , Manuel R. Blum
  • , Matthias Briel
  • , Beat Mueller
  • , Mirjam Christ-Crain
  • *Corresponding author for this work
  • Universitätsspital Basel
  • Cantonal Hospital Aarau
  • University of Bern
  • University of Basel
  • McMaster University

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)

Abstract

Objective: Glucocorticoids have been shown to improve outcome in community-acquired pneumonia (CAP). However, glucocorticoids have potential side-effects, and treatment response may vary. It is thus crucial to select patients with high likelihood to respond favourably. In critical illness, cosyntropin testing is recommended to identify patients in need for glucocorticoids. We investigated whether cosyntropin testing predicts treatment response to glucocorticoids in CAP. Design: Predefined secondary analysis of a randomized controlled trial. Patients: Hospitalized patients with CAP. Measurements: We performed 1 µg cosyntropin tests in a randomized trial comparing prednisone 50 mg for 7 days to placebo. We investigated whether subgroups based on baseline and stimulated cortisol levels responded differently to glucocorticoids with regard to time to clinical stability (TTCS) and other outcomes by inclusion of interaction terms into statistical models. Results: A total of 326 patients in the prednisone and 309 patients in the placebo group were evaluated. Neither basal cortisol nor a Δcortisol <250 nmol/L after stimulation nor the combination of basal cortisol and Δcortisol predicted treatment response as measured by TTCS (all P for interaction >0.05). Similarly, we found no effect modification with respect to mortality, rehospitalization, antibiotic treatment duration or CAP-related complications (all P for interaction >0.05). However, glucocorticoids had a stronger effect on shortening length of hospital stay in patients with a baseline cortisol of ≥938 nmol/L (P for interaction = 0.015). Conclusions: Neither baseline nor stimulated cortisol after low-dose cosyntropin testing at a dose of 1 µg predicted glucocorticoid responsiveness in mild to moderate CAP. A treatment decision for or against adjunct glucocorticoids in CAP should not be made depending on cortisol values or cosyntropin testing results.

Original languageEnglish
Pages (from-to)374-382
Number of pages9
JournalClinical Endocrinology
Volume91
Issue number3
DOIs
Publication statusPublished - 2019
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2018 John Wiley & Sons Ltd.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Cosyntropin testing does not predict response to glucocorticoids in community-acquired pneumonia in a randomized controlled trial'. Together they form a unique fingerprint.

Cite this